Read by QxMD icon Read

Future Oncology

Giammaria Fiorentini, Donatella Sarti, Riccardo Carandina, Luca Mulazzani, Cinzia Mincarelli, Roberto Candelari, Renato Argirò, Caterina Fiorentini, Camillo Aliberti
Transarterial chemoembolization (TACE) is indicated in unresectable hepatocellular carcinoma and allows the delivery of embolics inside tumor vascularization to reduce blood supply and release gradually the drug. This lowers the systemic exposure to chemotherapeutics, while increasing their local concentration and tissue necrosis that is higher than conventional TACE. The technology of TACE has seen the introduction of several types of embolics that are made of different materials. Available embolics for TACE include: drug-eluting beads (DC beads), acrylic copolymer, tris-acrylic microspheres and polyethylene glycol (PEG) microspheres...
November 16, 2018: Future Oncology
Dong Guo, Minghuan Li, Dawei Chen, Wang Jing, Hui Zhu, Lei Fu, Li Kong, Jinbo Yue, Jinming Yu
AIM: We aimed to investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy and determine which of the two was a better predictor of prognosis. MATERIALS & METHODS: We conducted multivariate Cox regression analysis to assess the independent effects of the NLR and PLR on patient survival. RESULTS: In multivariate Cox regression analysis, the NLR was an independent risk factor predicting poor prognostic factor (HR: 2...
November 15, 2018: Future Oncology
Hala T Borno, Eric J Small
High-risk nonmetastatic castration-resistant prostate cancer is a lethal disease that previously lacked clear treatment options. Progression to bone metastases is associated with significant morbidity and high cost. Apalutamide, an androgen receptor inhibitor, has substantial clinical response in nonmetastatic castration-resistant prostate cancer. Apalutamide + androgen deprivation therapy is well tolerated and improves metastasis-free survival, progression-free survival and time to symptomatic progression, and is associated with a favorable trend of improved overall survival...
November 14, 2018: Future Oncology
Bochao Zhao, Jingting Zhang, Jiale Zhang, Rui Luo, Zhenning Wang, Huimian Xu, Baojun Huang
AIM: To investigate whether the 8th edition of Tumor, Node, Metastasis (TNM) staging could properly evaluate the prognosis of gastric cancer patients. METHODS: The prognostic performance between the 7th and 8th edition of TNM staging was compared and clinicopathologic features were analyzed. RESULTS: The stage shifts in the 8th edition staging resulted in the increased numbers of stage IIIA patients and decreased numbers of stage IIB, stage IIIB and stage IIIC patients...
November 14, 2018: Future Oncology
Katherine Byrne, Giovanni Zanotti, Pamela Hallworth, Adam Roughley, Jean-Francois Martini, Roberto Uehara, Shrividya Iyer
AIM: To understand the treatment patterns and outcomes for stage IV squamous cell carcinoma of the head and neck, patients receiving second-line or later drug therapy. MATERIALS & METHODS: Real-world data were collected from 1152 patients in the USA, France, Germany and the UK through a retrospective chart analysis and patient-reported outcomes were collected using validated questionnaires in a subgroup of patients. RESULTS: Forty-four percent of patients had stage IVA/B disease...
November 14, 2018: Future Oncology
Jun Ge, Hang Dong, Ye Yang, Bin Liu, Min Zheng, Qing Cheng, Li Peng, Juan Li
AIM: To study the expression profile of NFIX, its prognostic value and the mechanism of its dysregulation in lung adenocarcinoma (LUAD). Patients & materials: A retrospective study was performed by using data from the Cancer Genome Atlas and the Human Protein Atlas. RESULTS: High NFIX RNA expression was an independent prognostic factor of favorable overall survival (HR: 0.687, 95% CI: 0.496-0.951; p = 0.024) and recurrence-free survival (HR: 0.700, 95% CI: 0...
November 12, 2018: Future Oncology
Soumen Khatua, Ross Magnum, Kelsey C Bertrand, Wafik Zaky, David McCall, Stephen C Mack
Advances in genomic, transcriptomic and epigenomic profiling now identifies pediatric ependymoma as a defined biological entity. Molecular interrogation has segregated these tumors into distinct biological subtypes based on anatomical location, age and clinical outcome, which now defines the need to tailor therapy even for histologically similar tumors. These findings now provide reasons for a paradigm shift in therapy, which should profile future clinical trials focused on targeted therapeutic strategies and risk-based treatment...
November 12, 2018: Future Oncology
Sandro Barni, Luca Livraghi, Maria Morritti, Patrizia Vici, Andrea Michelotti, Saverio Cinieri, Caterina Fontanella, Luca Porcu, Lucia Del Mastro, Fabio Puglisi
AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice...
November 9, 2018: Future Oncology
Rita Bonfiglio, Manuel Scimeca, Nicoletta Urbano, Elena Bonanno, Orazio Schillaci
No abstract text is available yet for this article.
November 9, 2018: Future Oncology
Vincenzo Di Nunno, Lidia Gatto, Benedetta Fragomeno, Marta Cubelli, Elisabetta Nobili, Ida Romano, Matteo Santoni, Salvatore Pisconti, Rodolfo Montironi, Francesco Massari
No abstract text is available yet for this article.
November 9, 2018: Future Oncology
Shinji Kohsaka, Mark Petronczki, Flavio Solca, Makoto Maemondo
While the development of EGFR-targeted tyrosine kinase inhibitors (TKIs) has revolutionized treatment of EGFR mutation-positive non-small-cell lung cancer, acquired resistance to therapy is inevitable, reflecting tumor evolution. Recent studies show that EGFR mutation-positive non-small-cell lung cancer is highly heterogeneous at the cellular level, facilitating clonal expansion of resistant tumors via multiple molecular mechanisms. Here, we review the mechanistic differences between first-, second- and third-generation EGFR-targeted TKIs and speculate how these features could explain differences in clinical activity between these agents from a clonal evolution perspective...
November 8, 2018: Future Oncology
Yasir Khan, Susan O'Brien
Acalabrutinib received an accelerated US FDA approval for patients with relapsed/refractory mantle cell lymphoma in 2017 and is currently being evaluated in chronic lymphocytic leukemia (CLL). To date, Ibrutinib is the only Bruton tyrosine kinase (BTK) inhibitor that's approved for treatment of CLL. Acalabrutinib is a second generation BTK inhibitor that binds covalently to the Cys481 residue on BTK and has half maximal inhibitory concentration (IC50 ) of 3 nM. In preclinical mouse models, acalabrutinib significantly reduced proliferation of CLL cells...
November 1, 2018: Future Oncology
Markus Moehler, Min-Hee Ryu, Mikhail Dvorkin, Keun-Wook Lee, Hasan Ş Coşkun, Rachel Wong, Hyun C Chung, Artem Poltoratsky, Akihito Tsuji, Chia Jui Yen, Alina S Muntean, Samuel Le Sourd, Gina M Vaccaro, Lindsay Overton, Narikazu Boku, Zev A Wainberg, Manish Patel, Maitreyi Sharma, Huiling Xiong, Ilaria Conti, Julien Taieb, Yung-Jue Bang
Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumab maintenance therapy or continue chemotherapy...
October 31, 2018: Future Oncology
Sherif Raouf, Gianfilippo Bertelli, Agnes Ograbek, Polly Field, Irwin Tran
AIM: This review aims to assist physicians and payers in assessing the efficacy and safety of bevacizumab in real-world clinical practice by identifying evidence on the comparative effectiveness and safety of bevacizumab in its most frequent indications. Materials & methods: In a systematic review of the published literature, electronic databases (Embase® , MEDLINE® and the Cochrane Library) were searched in May 2016 and updated in January 2017; 20 scientific congresses were searched in 2014-2017...
October 31, 2018: Future Oncology
San-Gang Wu, Wen-Wen Zhang, Jun Wang, Yong Dong, Jia-Yuan Sun, Yong-Xiong Chen, Zhen-Yu He
AIM: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). METHODS: We retrospectively assessed IBC patients from the SEER program. RESULTS: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype...
October 31, 2018: Future Oncology
Marcello Donati, Axel Stang, Gregor A Stavrou, Francesco Basile, Karl J Oldhafer
Until the 1980's, Klatskin tumors were considered 'desperate cases' and most of them were not resected; almost no oncologic concept was available. After many improvements, today, extended hepatectomy, including caudate lobe resection and lymphoadenectomy, have become a standard of care for oncologicaly radical resection of Klatskin tumors. Portal vein en bloc resection, if necessary, is a diffused standard assuring R0-resection without any improvement of survival in most series. Arterial resection remains episodical and controversial in its oncologic impact...
October 31, 2018: Future Oncology
Anna F Farago, Benjamin J Drapkin, Jose Antonio Lopez-Vilarino de Ramos, Carlos M Galmarini, Rafael Núñez, Carmen Kahatt, Luis Paz-Ares
Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. Early-phase clinical trials indicate promising activity of lurbinectedin in small-cell lung cancer. Here, we describe the rationale and design of ATLANTIS (NCT02566993), an open-label, randomized, multicenter Phase III study to compare the efficacy of lurbinectedin and doxorubicin combination with standard-of-care chemotherapy, investigator's choice of cyclophosphamide/doxorubicin/vincristine or topotecan, in patients with small-cell lung cancer that has progressed following one line of platinum-based chemotherapy...
October 26, 2018: Future Oncology
Barbara Moss
Barbara Moss speaks to Roshaine Wijayatunga, Senior Editor Oncology at the 2018 European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO GI; Barcelona). Barbara Moss is a Patient Ambassador for EuropaColon and Bowel Cancer UK. At the age of 52, in 2006, Barbara was diagnosed with stage IV colorectal cancer of the colon, spread to the liver and was told she had 3-5 months to live! Barbara is now an active campaigner and an active member of several organizations in the UK and Europe...
October 19, 2018: Future Oncology
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer
AIM: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. RESULTS: Overall median time on treatment was 27...
October 19, 2018: Future Oncology
Nicole A Carreau, Anna C Pavlick
As recently as 10 years ago, a diagnosis of metastatic melanoma was considered fatal, with a prognosis of typically 6 months or less from diagnosis. The development of checkpoint inhibitors, such as ipilimumab and nivolumab, which modulate the effects of the CTLA-4 and PD-1, respectively, has revolutionized outcomes for these patients. Monotherapy improves metastatic disease survival, but dual therapy provides greater benefit with 58% of patients alive at 3 years. Combination immunotherapy is even active in brain metastases...
October 18, 2018: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"